WHO interim policy guidance (as well as Expert Group meeting report) will be published online (www.who.int/tb/en) and disseminated through WHO listserves to WHO regional and country offices, Member States, the Stop TB Partnership, donors, technical agencies and other stakeholders.

To facilitate the implementation of this guidance, derivative products have been developed to complement existing guidance and tools for the management of MDR-TB, including monitoring and evaluation. In particular, a “How-to-use delamanid” document is part of the Companion handbook to the WHO guidelines for the programmatic management of drug-resistant tuberculosis (3). Of note, this document will include comparative tables on bedaquiline and delamanid, the two newest drugs for MDR-TB treatment, and a guide on how to use these drugs respectively.

This interim recommendation is valid for a maximum of two years and will be updated should additional data become available.